JP2010518095A - 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 - Google Patents
副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 Download PDFInfo
- Publication number
- JP2010518095A JP2010518095A JP2009549138A JP2009549138A JP2010518095A JP 2010518095 A JP2010518095 A JP 2010518095A JP 2009549138 A JP2009549138 A JP 2009549138A JP 2009549138 A JP2009549138 A JP 2009549138A JP 2010518095 A JP2010518095 A JP 2010518095A
- Authority
- JP
- Japan
- Prior art keywords
- dhe
- administration
- administered
- less
- max
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dispersion Chemistry (AREA)
Abstract
Description
片頭痛の診断では、3項目の片頭痛診断(ID Migraine)臨床判断ルールが策定されている。(非特許文献2)。片頭痛は一次性頭痛の一種で、一部の人では周期的に繰り返される。片頭痛は、悪心、嘔吐または光過敏などの症状を伴うため、他の頭痛とは異なる。ほとんどの人の場合、頭の片側だけに拍動痛を感じる。片頭痛は、「前兆を伴う」片頭痛か、「前兆を伴わない」片頭痛かのいずれかに分類される。前兆は一群の神経学的症状であり、通常、警告のサインになる視覚障害である。前兆が現れた患者は一般に、頭痛(headache pain)が始まる少し前に鮮やかな閃光または点滅する閃光が見える。しかしながら、片頭痛の人のほとんどは、そうした警告のサインを発しない。
ジヒドロエルゴタミン(DHE)は、1946以来片頭痛の処置に使用されている半合成麦角アルカロイドである。DHEは、生理的分子との構造類似性があるため、生体アミン受容体、特にセロトニン(5−HT)サブタイプ、アドレナリン(αおよびβ)サブタイプおよびドーパミン(D)サブタイプ)に対する作用を介した様々な薬理作用を持っている(表1)。
静脈内DHEの有効性および安全性を証明するため、成人を対象とした多く研究が行われてきた。重度の片頭痛を処置するためDHEの反復静脈内投与を用いてDHEを静脈内投与する現在の方法は、Raskinにより紹介された。(Raskin NH.Repetitive intravenous dihydroergotamine as therapy for intractable migraine.Neurology 1986;36:995−997)。本明細書において「直接的な静脈内送達」という場合、Raskin(Neurology 36:995−997(1986))に記載された手順に従ってDHEを直接IV投与することを指すと解釈する。
本明細書に記載の組成物については、たとえば、静脈内、動脈内、腹腔内、肺内、経口、吸入、膀胱内、筋肉内、気管内、皮下、眼内、髄膜内、経粘膜および経皮など、様々な経路により個体(ヒトなど)に投与できる。本発明の一実施形態では、以下に限定されるものではないが、経口、筋肉内、経皮、静脈内、吸入器または他の経気道送達系および同種のものなど許容可能な任意の経路により、本発明の化合物のナノ粒子(薬剤と一緒に製剤化されたタンパク質ナノ粒子または炭水化物ナノ粒子など)を投与してもよい。
本発明は、疼痛、悪心、音恐怖および光恐怖という片頭痛症候群の4つの主な症状を効果的かつ迅速に緩和する十分な投薬プロファイルが得られると同時に副作用を最小限にとどめるか消失させる、DHEの投与方法を教示する。発明者らが行った臨床試験では、予想外の現象が観察された。DHEを前述の要領で投与すると、意外にもピーク血漿濃度の著しい「急上昇」が回避され、悪心、胸部圧迫感または疼痛、血圧変動、嘔吐の副作用が最小限にとどまるか、あるいは、完全に消失しても、なお片頭痛の症状の迅速な緩和が得られた。
0=症状なし
1=軽度の症状(通常の日常生活を妨げない)
2=中等度の症状(通常の生活が一部制限される)
3=重度(通常の日常生活を送ることができなくなる)
の各段階でスコア評価する
頭痛(headache pain)の強度は、4段階の重症度スケール(0=疼痛なし、1=軽度、2=中等度、3=重度)で測定する。頭痛の改善(当初の強度よりも1段階下がる)までの平均経過時間、軽度の頭痛までの平均経過時間および頭痛なしまでの平均経過時間を測定する。効果的な片頭痛治療であれば、1.5〜2時間後には頭痛症状が軽度または頭痛なしに軽減されるであろう。
0=障害なし
1=やや障害がある
2=中等度の障害がある
3=重度または完全な障害がある
の4段階で測定する。
0=著しく改善
1=かなり改善
2=やや改善
3=変化なし
4=やや悪化
5=かなり悪化
6=著しく悪化
作用機序
実施例2および3に詳細に記載したCmax濃度で結合する受容体の調査から、有害作用プロファイルで観察される相違の根拠が得られた。理論に束縛されるものではないが、ドーパミン作動性受容体およびアドレナリン作動性受容体結合を最小限に抑えるようにCmax濃度を調節し、それにより副作用を回避しながら、片頭痛の症状の処置に効果があるセロトニン受容体への十分な結合を達成することで、副作用を起こさずにDHEで片頭痛を処置する方法を実現できると考えられる。
鎮痛の達成に必要なDHEの薬物動態プロファイル。
Cmax濃度における受容体結合
IV投与されたDHE(1mg)と吸入されたDHEとを比較した、臨床研究の示差的有害作用プロファイルを報告した(表2)。IV投薬後に有害作用の頻度が増大することが明白となった。ジヒドロエルゴタミンメシラート(DHE)の(1)静脈内注射と(2)吸入との間で薬理学的に生じる有害作用の相違を調べるため、臨床研究において吸入投薬および静脈内(IV)投薬後に報告されたCmaxレベルに一致する濃度に基づき、ジヒドロエルゴタミンメシラートの生体アミン受容体(セロトニン(5−HT)、アドレナリン、ドーパミン作動性)結合をインビトロで判定した。
ピーク血漿濃度に相当する濃度でのDHEによるセロトニン受容体、アドレナリン作動性受容体およびドーパミン作動性受容体への結合
放射性リガンド受容体結合アッセイを行うと、DHEが複数の受容体部位で広範囲な薬理作用を示すことが明確に明らかになる。(図3〜図5)。IVのCmaxに相当する濃度ではDHEは大部分の受容体に対して顕著な結合が認められるのに対し、吸入の結合では、各用量で異なるプロファイルが得られる。IVでない方法を用いて投与すると、ほとんどの場合、結合が減少する。
5−HT1Bサブタイプ受容体のアゴニストは、片頭痛および関連する症状の処置に有用であることが知られている。5−HT2B受容体は、片頭痛の発症において引き金の役割を果たしていることが知られている。図5は、高濃度対照(5μm)、IVのCmax(77.6nM)、4回の吸入のCmax(6.25nM)および非常に低濃度(0.25nM)における5−HT1Bおよび5−HT2B受容体の選択的アゴニズムを示す。5−HT1Bのアゴニズムはすべての濃度において維持され、効力が高いこと示されるのに対し、経口吸入のDHEでは5−HT2B受容体のアゴニズムは存在しない。
TEMPO(商標)吸入器を用いたDHE製剤の経肺投与
吸入送達用のDHE粒子の製造に大きな利点がある超臨界流体プロセスを用いてDHE粉末を作製し、単一のステップで所望の大きさの呼吸性粒子を製造する。(国際公開第2005/025506A2号を参照されたい。)処理後のDHE原薬の特徴は、超臨界流体処理した結晶の表面が極めて滑らかで表面エネルギーが小さく、したがって、噴射剤を用いた系で効果的に分散する傾向があることである。DHEのかなりの割合が確実に肺に沈着するように、微結晶の制御粒度を選択した。
Claims (52)
- 副作用を最小限にとどめながらDHEまたはその塩、水和物、多形、プロドラッグ、イオン対および代謝産物により個体の片頭痛を速やかに処置する方法であって、
片頭痛の症状の緩和が得られる十分な速度で一定量のDHE製剤を該個体に投与することを含み、
DHE投与の量および速度は副作用の有意な軽減の原因となる、
方法。 - DHE投与の量および速度は、DHEがセロトニン受容体に対してアゴニストとして働き片頭痛の症状が緩和されるような、DHEの循環血漿濃度レベルを生じるのに十分であり、
さらに、DHEの該循環血漿濃度レベルは、アドレナリン作動性受容体またはドーパミン作動性受容体または動脈収縮筋(arterial constrictor)セロトニン受容体に対して活発に結合して副作用を引き起こすのに必要なレベル未満にとどまる、請求項1に記載の方法。 - 前記副作用は、悪心、嘔吐、血管痙攣、感覚異常、高血圧、眩暈、不安症、呼吸困難、頭痛、潮紅、下痢、発疹、発汗増加、心弁膜症、胸膜および後腹膜線維症、有害な心血管作用、血圧不安定ならびに動脈収縮からなる群から選択される、請求項1に記載の方法。
- 前記副作用は、悪心および嘔吐からなる群から選択される、請求項1に記載の方法。
- 前記循環血漿濃度レベルのDHEは、ドーパミン作動性受容体の50%未満に活発に結合する、請求項2に記載の方法。
- 前記ドーパミン作動性受容体は、D1およびD2からなる群から選択される、請求項5に記載の方法。
- 前記副作用は、悪心および嘔吐からなる群から選択される、請求項5に記載の方法。
- 前記循環血漿濃度レベルのDHEは、ドーパミン作動性受容体の20%未満に活発に結合する、請求項2に記載の方法。
- 前記ドーパミン作動性受容体は、D1およびD2からなる群から選択される、請求項8に記載の方法。
- 前記副作用は、悪心および嘔吐からなる群から選択される、請求項8に記載の方法。
- 前記循環血漿濃度レベルのDHEは、5−HT3受容体の20%未満に活発に結合する、請求項2に記載の方法。
- 前記副作用は悪心である、請求項11に記載の方法。
- 前記循環血漿濃度レベルのDHEは、動脈収縮筋セロトニン受容体の20%未満に活発に結合する、請求項2に記載の方法。
- 前記動脈収縮筋セロトニン受容体は、5−HT2A受容体である、請求項13に記載の方法。
- 前記動脈収縮筋セロトニン受容体は、5−HT2B受容体である、請求項13に記載の方法。
- 前記副作用は、血管収縮状態および心血管系状態からなる群から選択される、請求項13に記載の方法。
- 前記循環血漿濃度レベルのDHEは、アドレナリン作動性受容体の60%未満に活発に結合する、請求項2に記載の方法。
- 前記循環血漿濃度レベルのDHEは、アドレナリン作動性受容体の20%未満に活発に結合する、請求項17に記載の方法。
- 前記副作用は、血管収縮状態、血圧上昇状態および心血管系状態からなる群から選択される、請求項17に記載の方法。
- 前記循環血漿濃度レベルのDHEは、片頭痛の症状の緩和が得られる十分なレベルで5−HT1A、5、−HT1Bおよび5−HT1Dからなる群から選択されるセロトニン受容体に活発に結合する、請求項2に記載の方法。
- 前記DHEは、ピーク血漿濃度(Cmax)がヒトの循環血漿中15,000pg/ml未満の濃度であり、かつ投与後に該ピーク血漿濃度に達する時間(Tmax)が投与後30分未満であるような速度で投与される、請求項1に記載の方法。
- DHEの前記Cmaxが循環血漿中10,000pg/mL未満である、請求項21に記載の方法。
- DHEの前記Cmaxが循環血漿中7,500pg/mL未満である、請求項21に記載の方法。
- 前記DHEは、循環血漿中のDHEのTmaxが20分未満であるような速度で投与される、請求項21に記載の方法。
- 前記DHEは、DHEのピーク血漿濃度(Cmax)が、直接的な静脈内送達により投与されるDHEのCmaxから少なくとも10分の1に低減するような速度で投与される、請求項1に記載の方法。
- 前記DHEは、DHEのピーク血漿濃度(Cmax)が、直接的な静脈内送達により投与されるDHEのTmaxよりも少なくとも1分遅延するような速度で投与される、請求項1に記載の方法。
- 前記CmaxレベルおよびTmaxレベルが得られるDHEの前記投与により、疼痛、悪心、音恐怖および光恐怖からなる群から選択される片頭痛症候群の少なくとも一部が緩和し、該緩和は30分以内に得られ、さらに薬剤によって誘発される悪心、心血管系副作用または他の有害作用が軽減される、請求項24に記載の方法。
- 片頭痛症候群の前記緩和は、DHEの投与時に「0」を超える片頭痛症状についてのIHSスコアが投与30分後、60分後、90分後または120分後に≦1のスコアに低下することで測定される、請求項1に記載の方法。
- 2.0mg未満のDHEまたはその塩、水和物、多形 プロドラッグ、イオン対および代謝産物の単位用量が投与される、請求項1に記載の方法。
- 2.0mg未満のDHEまたはその塩、水和物、多形 プロドラッグ、イオン対および代謝産物の単位用量が投与され、送達された薬剤の体循環中の該薬剤の濃度対時間の曲線の面積(AUC)が匹敵する静脈内(IV)送達用量の75%以内である、請求項14に記載の方法。
- 前記投与の結果、DHEの一次活性代謝産物におけるピーク血漿濃度がCmaxで1,000pg/ml未満となる、請求項1に記載の方法。
- DHEの前記一次活性代謝産物は、8−ヒドロキシ−ジヒドロエルゴタミンである、請求項31に記載の方法。
- 前記一次代謝産物のCmaxが循環血漿中500pg/mL未満である、請求項31に記載の方法。
- 前記一次代謝産物のCmaxが循環血漿中200pg/mL未満である、請求項31に記載の方法。
- 前記一次代謝産物のTmaxが循環血漿中90分未満である、請求項31に記載の方法。
- DHEまたはその塩、水和物、多形、プロドラッグ、イオン対および代謝産物を含む製剤であって、請求項1に記載の方法による投与に好適な製剤。
- 片頭痛の症状が緩和されるように、セロトニン受容体に対するアゴニストとして有効なDHEの循環血漿濃度レベルを生じるのに十分な量での前記DHE製剤の投与は、該循環血漿濃度レベルのDHEが、副作用を引き起こすレベルでアドレナリン作動性受容体またはドーパミン作動性受容体または動脈収縮筋セロトニン受容体に結合することを引き起こさない、請求項36に記載の製剤。
- 前記DHE製剤は、静脈内投与、動脈内投与、腹腔内投与、肺内投与、経口投与、舌下投与、口腔投与、鼻腔内投与、経口吸入投与、膀胱内投与、筋肉内投与、気管内投与、皮下投与、イオン導入投与および経皮投与からなる群から選択される様式で投与される、請求項1に記載の方法。
- 前記DHE製剤は、エアロゾル、乾燥粉末吸入器、ネブライザー、気化器または加圧式定量吸入器(pMDI)を含む肺吸入により投与される、請求項38に記載の方法。
- 前記DHE製剤は、呼吸作動型定量吸入器により投与される、請求項38に記載の方法。
- 前記DHE製剤は、静脈内投与、動脈内投与、腹腔内投与、肺内投与、経口投与、舌下投与、口腔投与、鼻腔内投与、経口吸入投与、膀胱内投与、筋肉内投与、気管内投与、皮下投与、イオン導入投与および経皮投与からなる群から選択される様式で投与され、
さらに、前記DHEは、ピーク血漿濃度(Cmax)がヒトの循環血漿中10,000pg/ml未満の濃度であり、かつ投与後に該ピーク血漿濃度に達する時間(Tmax)が投与後30分未満であるような速度で投与される、請求項1に記載の方法。 - 前記DHE製剤は、エアロゾル、乾燥粉末吸入器、ネブライザー、気化器または加圧式定量吸入器(pMDI)を含む肺吸入により投与される、請求項41に記載の方法。
- 前記DHE製剤は、呼吸作動型定量吸入器により投与される、請求項42に記載の方法。
- 前記DHE製剤は、前記個体に制吐薬を投与せずに投与される、請求項43に記載の方法。
- 前記DHE製剤は、呼吸作動型定量吸入器により個体に投与され、
前記DHEは、ピーク血漿濃度(Cmax)がヒトの循環血漿中10,000pg/ml未満の濃度であり、投与後に該ピーク血漿濃度に達する時間(Tmax)が投与後20分未満であるような速度で投与され、
さらに、該DHE製剤は、制吐薬を該個体に投与せずに投与される、請求項1に記載の方法。 - 単位用量のDHEまたはその塩、水和物、多形、プロドラッグ、イオン対および代謝産物を含むキットであって、該単位用量は、ヒト個体に投与される場合、DHE投与の量および速度が副作用を引き起こさない条件下で片頭痛の症状の緩和を得るのに十分である、キット
- 吸入器装置をさらに含む、請求項46に記載のキット。
- ネブライザーをさらに含む、請求項46に記載のキット。
- 加圧式定量吸入器をさらに含む、請求項46に記載のキット。
- 1つまたは複数の単位用量のDHE製剤を含む吸入器装置であって、各単位用量は、ピーク血漿濃度(Cmax)がヒトの循環血漿中10,000pg/ml未満の濃度であり、かつ投与後に該ピーク血漿濃度に達する時間(Tmax)が投与後30分未満であるような速度で投与される、吸入器装置。
- 前記DHE製剤は密封容器で提供される、請求項50に記載の吸入器装置。
- 化合物を用いて個体の疾患または状態を速やかに処置するための方法であって、
ここで、該化合物は(a)1種または複数種の第1の受容体に結合し、該第1の受容体への該化合物の結合は該疾患または状態を緩和し、かつ(b)1種または複数種の第2の受容体に結合し、該第2の受容体への該化合物の結合は副作用を引き起こし、
該方法は、
化合物が該第1の受容体に対してアゴニストとして働き、該疾患または状態の緩和を提供するように、該化合物の循環血漿濃度レベルを生じるのに十分な速度で一定量の該化合物を該個体に投与することを含み、
該化合物の該循環血漿濃度レベルは、該第2の受容体に対する結合が副作用を引き起こすのに必要なレベル未満にとどまる、
方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90085007P | 2007-02-11 | 2007-02-11 | |
US60/900,850 | 2007-02-11 | ||
PCT/US2008/001829 WO2008097664A1 (en) | 2007-02-11 | 2008-02-11 | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013162032A Division JP5908439B2 (ja) | 2007-02-11 | 2013-08-05 | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010518095A true JP2010518095A (ja) | 2010-05-27 |
JP2010518095A5 JP2010518095A5 (ja) | 2012-03-01 |
JP5825757B2 JP5825757B2 (ja) | 2015-12-02 |
Family
ID=39400937
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009549138A Active JP5825757B2 (ja) | 2007-02-11 | 2008-02-11 | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
JP2013162032A Active JP5908439B2 (ja) | 2007-02-11 | 2013-08-05 | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
JP2015236885A Active JP6209198B2 (ja) | 2007-02-11 | 2015-12-03 | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
JP2015236886A Pending JP2016040317A (ja) | 2007-02-11 | 2015-12-03 | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013162032A Active JP5908439B2 (ja) | 2007-02-11 | 2013-08-05 | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
JP2015236885A Active JP6209198B2 (ja) | 2007-02-11 | 2015-12-03 | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
JP2015236886A Pending JP2016040317A (ja) | 2007-02-11 | 2015-12-03 | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
Country Status (19)
Country | Link |
---|---|
US (10) | US8148377B2 (ja) |
EP (3) | EP2425819A1 (ja) |
JP (4) | JP5825757B2 (ja) |
KR (3) | KR20160106200A (ja) |
CN (2) | CN104188907A (ja) |
AU (3) | AU2008214205B2 (ja) |
CA (1) | CA2677838C (ja) |
CY (1) | CY1116546T1 (ja) |
DK (2) | DK2425820T3 (ja) |
ES (2) | ES2691033T3 (ja) |
HK (1) | HK1204918A1 (ja) |
HU (1) | HUE026884T2 (ja) |
IL (1) | IL200333A (ja) |
MX (1) | MX2009008582A (ja) |
PL (1) | PL2425820T3 (ja) |
PT (1) | PT2425820E (ja) |
SI (1) | SI2425820T1 (ja) |
WO (1) | WO2008097664A1 (ja) |
ZA (1) | ZA200905628B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013224331A (ja) * | 2007-02-11 | 2013-10-31 | Map Pharmaceuticals Inc | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
JP2021510155A (ja) * | 2018-01-05 | 2021-04-15 | インペル ニューロファーマ インコーポレイテッド | 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
CA2538237A1 (en) * | 2003-09-10 | 2005-03-24 | Map Pharmaceuticals, Inc. | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
EP2247330B1 (en) | 2008-02-07 | 2017-09-20 | The University of Washington | Circumferential aerosol device |
US20110082150A1 (en) * | 2008-02-11 | 2011-04-07 | Robert Owen Cook | Headache pre-emption by dihydroergotamine treatment during headache Precursor events |
WO2010151804A1 (en) * | 2009-06-26 | 2010-12-29 | Map Pharmaceuticals, Inc. | Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
IN2012DN04858A (ja) * | 2009-12-23 | 2015-09-25 | Map Pharmaceuticals Inc | |
BR112013022249B8 (pt) | 2011-03-03 | 2022-10-25 | Impel Neuropharma Inc | Dispositivo de distribuição de droga nasal |
BR112013028572B8 (pt) | 2011-05-09 | 2022-10-25 | Impel Neuropharma Inc | Bocais para distribuição de droga nasal |
CN103827113A (zh) * | 2011-06-23 | 2014-05-28 | Map药物公司 | 新型氟麦角碱类似物 |
AU2012355982A1 (en) | 2011-12-19 | 2014-07-10 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
AU2012355983A1 (en) | 2011-12-21 | 2015-01-22 | Map Pharmaceuticals, Inc. | Novel neuromodulatory compounds |
US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
US9394314B2 (en) | 2012-12-21 | 2016-07-19 | Map Pharmaceuticals, Inc. | 8′-hydroxy-dihydroergotamine compounds and compositions |
AU2013361345A1 (en) * | 2012-12-21 | 2015-07-09 | Map Pharmaceuticals, Inc. | Novel ergoline derivatives and uses thereof |
US20140179705A1 (en) * | 2012-12-21 | 2014-06-26 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
EP2991713B1 (en) | 2013-04-28 | 2019-06-19 | Impel Neuropharma Inc. | Medical unit dose container |
JP6753927B2 (ja) | 2015-09-10 | 2020-09-09 | インペル ニューロファーマ インコーポレイテッド | 直列形経鼻送達デバイス |
JP2021503988A (ja) | 2017-11-21 | 2021-02-15 | インペル ニューロファーマ インコーポレイテッド | インレットインターフェースを用いた鼻腔内装置 |
EP3713628A4 (en) | 2017-11-21 | 2021-08-18 | Impel Neuropharma Inc. | INTRA-NASAL DEVICE WITH DIVER TUBE |
CN111836615A (zh) | 2018-01-05 | 2020-10-27 | 英倍尔药业股份有限公司 | 通过精密鼻装置的奥氮平的鼻内递送 |
US11083712B1 (en) | 2018-03-20 | 2021-08-10 | Relevale, Inc. | Low concentration delivery of an ergoline derivative for treatment of a headache |
KR20210034047A (ko) | 2018-07-19 | 2021-03-29 | 임펠 뉴로파마 인코포레이티드 | 파킨슨 병 치료를 위한 레보도파 및 도파 데카르복실라아제 저해제의 기도 전달 |
CN113423400A (zh) * | 2018-12-11 | 2021-09-21 | 小蜜橘制药公司 | 用于治疗或预防头痛的组合物、装置和方法 |
EA202191856A1 (ru) | 2019-01-03 | 2021-09-02 | Импел Ньюрофарма, Инк. | Устройство для назальной доставки лекарственных средств |
EP3969085A4 (en) | 2019-05-17 | 2023-06-21 | Impel Pharmaceuticals Inc. | DISPOSABLE NASAL DELIVERY DEVICE |
US11786512B2 (en) | 2019-09-23 | 2023-10-17 | Slayback Pharma Llc | Stable pharmaceutical compositions of dihydroergotamine mesylate |
WO2021133744A1 (en) * | 2019-12-23 | 2021-07-01 | Scienture, Inc. | Dihydroergotamine mesylate formulations and pre-filled injectors for therapeutic delivery of the same |
CN115279371A (zh) * | 2020-01-14 | 2022-11-01 | 英倍尔制药公司 | 重复施用双氢麦角胺治疗频繁偏头痛 |
KR20230152083A (ko) * | 2021-03-03 | 2023-11-02 | 풀매트릭스 오퍼레이팅 컴퍼니, 인크 | 다이하이드로에르고타민 건조 분말 제형 및 사용 방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005025506A2 (en) * | 2003-09-10 | 2005-03-24 | Map Pharmaceuticals, Inc. | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
Family Cites Families (359)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US147389A (en) * | 1874-02-10 | Improvement in sawing-machines | ||
US605674A (en) | 1898-06-14 | Combined pencil-case and comb-case | ||
BE555319A (ja) | 1956-03-21 | 1900-01-01 | ||
US2885427A (en) | 1956-11-15 | 1959-05-05 | Dow Chemical Co | Fluorination of trichloroethylene |
BE556587A (ja) | 1957-01-31 | 1957-04-11 | ||
US2865427A (en) | 1957-05-10 | 1958-12-23 | Robert E Garfield | Sliding automobile seat attachment |
BE629985A (ja) | 1962-11-29 | |||
US3320125A (en) | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
US3261748A (en) | 1964-07-17 | 1966-07-19 | Dow Chemical Co | 1,1,1,2-tetrafluoroethane anesthetic |
GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
US3895111A (en) | 1973-06-27 | 1975-07-15 | American Cyanamid Co | Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate |
US3809294A (en) | 1973-06-27 | 1974-05-07 | American Cyanamid Co | Dispensing lung contacting powdered medicaments |
US3994421A (en) | 1975-09-29 | 1976-11-30 | American Cyanamid Company | Unitary therapeutic aerosol dispenser |
US4405598A (en) | 1976-01-30 | 1983-09-20 | Fisons, Limited | Composition for treating asthma |
FI770215A (ja) | 1976-01-30 | 1977-07-31 | Fisons Ltd | |
NL7708731A (nl) | 1976-08-13 | 1978-02-15 | Montedison Spa | Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen. |
JPS5325284A (en) | 1976-08-19 | 1978-03-08 | Daikin Ind Ltd | Aerosol composition |
DE2750090A1 (de) | 1976-11-19 | 1978-06-01 | Sandoz Ag | Neue verabreichungsformen fuer organische verbindungen |
GB2001334B (en) | 1977-07-19 | 1982-03-03 | Fisons Ltd | Pressurised aerosol formulation |
US4129603A (en) | 1978-02-07 | 1978-12-12 | Imperial Chemical Industries Limited | Manufacture of halogenated compounds |
US4241048A (en) | 1979-05-01 | 1980-12-23 | Bristol-Myers Company | Suspension composition of benzocaine |
IT1121513B (it) | 1979-05-28 | 1986-04-02 | Chiesi Farma Spa | Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol |
JPS6034925B2 (ja) | 1979-07-31 | 1985-08-12 | 帝人株式会社 | 持続性鼻腔用製剤およびその製造法 |
ZA81976B (en) | 1980-02-15 | 1982-07-28 | Glaxo Group Ltd | Androstane carbothioates |
US4352789A (en) | 1980-03-17 | 1982-10-05 | Minnesota Mining And Manufacturing Company | Aerosol compositions containing finely divided solid materials |
WO1981002975A1 (en) | 1980-04-21 | 1981-10-29 | Univ California | Prolonged action drug formulation |
EP0039369B1 (en) | 1980-05-02 | 1983-06-15 | Schering Corporation | Beclomethasone ester solvates, process for their preparation, and preparation of a formulation |
DE3017101C2 (de) | 1980-05-03 | 1983-07-21 | PS Pharma Maschinen und Geräte GmbH, 6800 Mannheim | Dragierwand |
FI63672C (fi) | 1980-05-19 | 1983-08-10 | Orion Yhtymae Oy | Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan |
US4311863A (en) | 1980-06-11 | 1982-01-19 | E. I. Du Pont De Nemours & Company | Process for the manufacture of 1,1,1,2-tetrafluoroethane |
GB2078422B (en) | 1980-06-19 | 1983-12-21 | Standard Telephones Cables Ltd | Matrix addressing of display devices |
US4710495A (en) | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
US4423099A (en) | 1980-07-28 | 1983-12-27 | Ciba-Geigy Corporation | Membrane modified hydrogels |
NZ197996A (en) | 1980-08-12 | 1985-08-16 | Glaxo Group Ltd | 1-(3-(omega-aminoalkyl)-1h-indol-5-yl)alkanamides |
CY1492A (en) | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
EP0072046B1 (en) | 1981-07-24 | 1986-01-15 | FISONS plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
GB2105189B (en) | 1981-07-24 | 1985-03-20 | Fisons Plc | Inhalation drugs |
KR890000664B1 (ko) | 1981-10-19 | 1989-03-22 | 바리 안소니 뉴우샘 | 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법 |
JPS5921613A (ja) | 1982-07-28 | 1984-02-03 | Takeda Chem Ind Ltd | 直腸投与製剤 |
US4659696A (en) | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4582731A (en) | 1983-09-01 | 1986-04-15 | Battelle Memorial Institute | Supercritical fluid molecular spray film deposition and powder formation |
GB8332435D0 (en) | 1983-12-06 | 1984-01-11 | Glaxo Group Ltd | Chemical compounds |
US4514574A (en) | 1984-01-09 | 1985-04-30 | The Dow Chemical Company | Process for separating isomeric mixtures |
JPS60224638A (ja) | 1984-04-23 | 1985-11-09 | Kao Corp | 経皮吸収促進剤およびこれを含有する外用剤 |
JPS60227805A (ja) | 1984-04-26 | 1985-11-13 | Mitsubishi Plastics Ind Ltd | 複合ダイヤフラム |
US4629478A (en) | 1984-06-22 | 1986-12-16 | Georgia Tech Research Corporation | Monodisperse aerosol generator |
KR880001237B1 (ko) | 1984-07-25 | 1988-07-12 | 호비온 인터 리미티드 | 베클로메타손 17,21-디프로피오네이트의 용매화합물의 제조방법 |
GB8432063D0 (en) | 1984-12-19 | 1985-01-30 | Riker Laboratories Inc | Physically modified steroids |
GB8501015D0 (en) | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
US5069911A (en) | 1985-02-05 | 1991-12-03 | Sandoz Ltd. | Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
US5021428A (en) | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
US4737384A (en) | 1985-11-01 | 1988-04-12 | Allied Corporation | Deposition of thin films using supercritical fluids |
JP2765700B2 (ja) | 1986-08-11 | 1998-06-18 | イノベータ・バイオメド・リミテツド | マイクロカプセルを含有する医薬調合物 |
US5200413A (en) | 1987-01-05 | 1993-04-06 | Beecham Group P.L.C. | Indolyl carboxamides useful treating migraine, cluster headache, trigeminal neuralgia or emesis |
US4767612A (en) | 1987-01-23 | 1988-08-30 | Rorer Pharmaceutical Corporation | Triamcinolone acetonide for the treatment of allergic rhinitis |
US4851595A (en) | 1987-07-07 | 1989-07-25 | E. I. Du Pont De Nemours And Company | Liquid phase halogen exchange process for the manufacture of 1,1,1,2-tetrafluoroethane |
IT1222509B (it) | 1987-08-17 | 1990-09-05 | Miat Spa | Insufflatore per la somministrazione di farmaci sotto forma di polvere predosata in opercoli |
US5364863A (en) | 1987-09-08 | 1994-11-15 | Eli Lilly And Company | Specific 5-HT3 antagonists |
US4963557A (en) | 1987-09-28 | 1990-10-16 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
DE3787533T2 (de) | 1987-12-21 | 1994-01-20 | Union Carbide Corp | Verwendung von superkritischen Flüssigkeiten als Verdünner beim Aufsprühen von Überzügen. |
DE3744329A1 (de) | 1987-12-28 | 1989-07-06 | Schwarz Pharma Gmbh | Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung |
JPH01176437A (ja) | 1987-12-29 | 1989-07-12 | Ono Pharmaceut Co Ltd | 有機物質の微粒化方法 |
DE3823378A1 (de) | 1988-07-09 | 1990-01-11 | Knoll Ag | (s)-emopamil zur anwendung bei der behandlung von migraene |
US5066522A (en) | 1988-07-14 | 1991-11-19 | Union Carbide Chemicals And Plastics Technology Corporation | Supercritical fluids as diluents in liquid spray applications of adhesives |
US5206268A (en) | 1988-08-16 | 1993-04-27 | Burroughs Wellcome Co. | Medicaments |
GB8820398D0 (en) | 1988-08-27 | 1988-09-28 | Fisons Plc | Pharmaceutical formulation |
US5707634A (en) | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
JP2843857B2 (ja) | 1988-10-05 | 1999-01-06 | ファルマシア・アンド・アップジョン・カンパニー | 反溶剤への沈澱を介する微細分化固体結晶性粉末 |
US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8828544D0 (en) | 1988-12-07 | 1989-01-11 | Ici Plc | Chemical process |
GB8900267D0 (en) | 1989-01-06 | 1989-03-08 | Riker Laboratories Inc | Narcotic analgesic formulations and apparatus containing same |
US5011678A (en) | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
DE3905726A1 (de) | 1989-02-24 | 1990-08-30 | Hoechst Ag | Druckgaspackung und treibmittel fuer aerosole |
GB8904370D0 (en) | 1989-02-25 | 1989-04-12 | Cosmas Damian Ltd | Liquid delivery compositions |
SE466684B (sv) | 1989-03-07 | 1992-03-23 | Draco Ab | Anordning vid en inhalator samt foerfarande foer att med anordningen registrera medicinering med inhalator |
GB8908250D0 (en) | 1989-04-12 | 1989-05-24 | Fisons Plc | Formulations |
GB8909891D0 (en) | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
AU643435B2 (en) | 1989-04-28 | 1993-11-18 | Riker Laboratories, Inc. | Dry powder inhalation device |
US4945119A (en) | 1989-05-10 | 1990-07-31 | The Dow Chemical Company | Foaming system for rigid urethane and isocyanurate foams |
US4940171A (en) | 1989-05-18 | 1990-07-10 | Gilroy Gordon C | Aerosol package having compressed gas propellant and vapor tap of minute size |
US5176878A (en) | 1989-05-23 | 1993-01-05 | Teledyne Industries, Inc. | Zirconium-hafnium separation process |
AU633584B2 (en) | 1989-06-15 | 1993-02-04 | Tokyo Tanabe Company Limited | Aerosols of pyrido(1,2-a)pyrimidine compounds |
US5232707A (en) | 1989-07-10 | 1993-08-03 | Syntex (U.S.A.) Inc. | Solvent extraction process |
US4916125A (en) | 1989-07-11 | 1990-04-10 | Sandoz Ltd. | Method of treating migraine |
US5130137A (en) | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
GB8918879D0 (en) | 1989-08-18 | 1989-09-27 | Danbiosyst Uk | Pharmaceutical compositions |
US5225163A (en) | 1989-08-18 | 1993-07-06 | Angenics, Inc. | Reaction apparatus employing gravitational flow |
EP0500538B1 (en) | 1989-08-18 | 1999-12-08 | Foster Miller, Inc. | Vessel construction |
US5238920A (en) | 1989-08-22 | 1993-08-24 | Abbott Laboratories | Pulmonary surfactant protein fragments |
GB2235627B (en) | 1989-09-08 | 1993-09-01 | Glaxo Group Ltd | Inhalation medicaments for treating respiratory disorders |
US5270305A (en) | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5223264A (en) | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5106659A (en) | 1989-10-04 | 1992-04-21 | Nordson Corporation | Method and apparatus for spraying a liquid coating containing supercritical fluid or liquified gas |
US5439670A (en) | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB9001635D0 (en) | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
US5376386A (en) | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
DE4003270A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgase und ihre verwendung in arzneimittelzubereitungen |
IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
DE4004904A1 (de) | 1990-02-16 | 1990-09-13 | Gerhard Brendel | Trommel-applikator |
EP0526481B1 (en) | 1990-03-23 | 1995-04-26 | Minnesota Mining And Manufacturing Company | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US5118494A (en) | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US4970093A (en) | 1990-04-12 | 1990-11-13 | University Of Colorado Foundation | Chemical deposition methods using supercritical fluid solutions |
US5123924A (en) * | 1990-04-25 | 1992-06-23 | Spire Corporation | Surgical implants and method |
JP3122671B2 (ja) | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
SI21560B (sl) | 1990-06-07 | 2005-04-30 | Astrazeneca Ab | 3,5-disubstituirani indolni derivati kot "5-HT1-podobni" receptorski agonisti |
ES2078447T3 (es) | 1990-06-15 | 1995-12-16 | Merck & Co Inc | Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales. |
US5273579A (en) | 1990-06-19 | 1993-12-28 | Mitsubishi Mining And Cement Co., Ltd. | Quick setting compositions |
EP0536204B1 (en) | 1990-06-27 | 1994-04-06 | Minnesota Mining And Manufacturing Company | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
CA2020018A1 (en) | 1990-06-27 | 1991-12-28 | Don L. Simmons | Method and composition for treating the migraine complex |
IL98639A0 (en) | 1990-06-28 | 1992-07-15 | Glaxo Inc | Aerosol drug formulations |
US5126123A (en) | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
DE69131855T2 (de) | 1990-06-29 | 2000-04-13 | Sony Corp | Aufzeichnungs-/Wiedergabesystem für eine magneto-optische Platte |
IE912220A1 (en) | 1990-06-29 | 1992-01-01 | Fisons Plc | Pressurised Aerosol Compositions |
GB9017155D0 (en) | 1990-08-03 | 1990-09-19 | Ici Plc | Spray drying |
US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
MX9203481A (es) | 1990-10-18 | 1992-07-01 | Minnesota Mining & Mfg | Formulaciones. |
EP0553298B1 (en) | 1990-10-18 | 1994-11-17 | Minnesota Mining And Manufacturing Company | Aerosol formulation comprising beclomethasone 17,21 dipropionate |
US5919435A (en) | 1990-11-09 | 1999-07-06 | Glaxo Group Limited | Aerosol formulation containing a particulate medicament |
GB9024365D0 (en) | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
GB9024366D0 (en) | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
US5254755A (en) | 1990-12-04 | 1993-10-19 | Allied-Signal Inc. | Partially fluorinated alkanols having a tertiary structure |
DE4118230A1 (de) | 1990-12-20 | 1992-06-25 | Bayer Ag | Verfahren zur isolierung von polymeren aus ihren loesungsmitteln mit kohlendioxid-haltigen fluessigkeiten |
US5290539A (en) | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
US6006745A (en) | 1990-12-21 | 1999-12-28 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
DE4041563A1 (de) | 1990-12-22 | 1992-06-25 | Sanol Arznei Schwarz Gmbh | Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren |
US5317103A (en) | 1991-01-15 | 1994-05-31 | Merck Sharp & Dohme Limited | Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5190029A (en) | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
US5182097A (en) | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
EP0504112A3 (en) | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
US5186164A (en) | 1991-03-15 | 1993-02-16 | Puthalath Raghuprasad | Mist inhaler |
US5182040A (en) | 1991-03-28 | 1993-01-26 | E. I. Du Pont De Nemours And Company | Azeotropic and azeotrope-like compositions of 1,1,2,2-tetrafluoroethane |
GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
US5491148A (en) | 1991-04-26 | 1996-02-13 | Syntex (U.S.A.) Inc. | Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists |
DE4117751A1 (de) | 1991-05-30 | 1992-12-03 | Bayer Ag | Verfahren zur isolierung von polycarbonaten |
JPH06508149A (ja) | 1991-06-10 | 1994-09-14 | シェリング・コーポレーション | クロロフルオロカーボン不含エーロゾル製剤 |
WO1992022288A1 (en) | 1991-06-10 | 1992-12-23 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
AU2178392A (en) | 1991-06-12 | 1993-01-12 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
GB9113802D0 (en) | 1991-06-26 | 1991-08-14 | Smithkline Beecham Plc | Medicaments |
AU662919B2 (en) | 1991-07-02 | 1995-09-21 | Inhale, Inc. | Method and device for delivering aerosolized medicaments |
US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
IL103238A (en) | 1991-09-25 | 1995-07-31 | Fisons Plc | Pressed aerosol preparations |
US6123924A (en) | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
US6063910A (en) | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
US5674471A (en) | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Aerosol formulations containing P134a and salbutamol |
ES2079210T3 (es) | 1991-12-12 | 1996-01-01 | Glaxo Group Ltd | Formulacion farmaceutica de aerosol. |
IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
US5736124A (en) | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
US5653962A (en) | 1991-12-12 | 1997-08-05 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
US5916540A (en) | 1994-10-24 | 1999-06-29 | Glaxo Group Limited | Aerosol formulations containing P134A and/or P227 and particulate medicament |
US5744123A (en) | 1991-12-12 | 1998-04-28 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
CA2421976C (en) | 1991-12-12 | 2004-04-20 | Glaxo Group Limited | Medicaments |
AU675633B2 (en) | 1991-12-18 | 1997-02-13 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
CA2084531A1 (en) | 1991-12-19 | 1993-06-20 | David W. Smith | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines |
GB9200148D0 (en) | 1992-01-06 | 1992-02-26 | Minnesota Mining & Mfg | Aerosol valves |
US5320094A (en) | 1992-01-10 | 1994-06-14 | The Johns Hopkins University | Method of administering insulin |
US5202110A (en) | 1992-01-22 | 1993-04-13 | Virginia Commonwealth University | Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants |
GB9202519D0 (en) | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
US5196575A (en) | 1992-02-19 | 1993-03-23 | Hoechst Celanese Corp. | Supercritical separation of isomers of functional organic compounds at moderate conditions |
US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
US5242949A (en) | 1992-03-13 | 1993-09-07 | Rugby-Darby Group Companies, Inc. | Treating classic migraine |
JPH05280282A (ja) | 1992-03-31 | 1993-10-26 | Kubota Corp | 埋設管の地中引き込み装置 |
ATE222754T1 (de) | 1992-06-12 | 2002-09-15 | Teijin Ltd | Ultrafeines pulver zur inhalation und dessen herstellung |
US5376359A (en) | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
US5833950A (en) | 1992-07-31 | 1998-11-10 | Glaxo Group Limited | Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate |
MX9304585A (es) | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. |
US5314682A (en) | 1992-09-21 | 1994-05-24 | Great Lakes Chemical Corp. | Ozone friendly sterilant mixture |
WO1994007514A1 (en) | 1992-09-29 | 1994-04-14 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
AU5171293A (en) | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
WO1994009913A1 (en) | 1992-11-02 | 1994-05-11 | Ferro Corporation | Method of preparing coating materials |
GB9226474D0 (en) | 1992-12-18 | 1993-02-10 | Ici Plc | Production of particulate materials |
DK154092D0 (da) | 1992-12-23 | 1992-12-23 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
US5364838A (en) | 1993-01-29 | 1994-11-15 | Miris Medical Corporation | Method of administration of insulin |
US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
DE59308043D1 (de) | 1993-02-24 | 1998-02-26 | Sulzer Chemtech Ag | Reinigung von salzbeladenem Abwasser durch Nassoxidation bei superkritischen Bedingungen |
US6162234A (en) | 1993-03-23 | 2000-12-19 | Freedland; Yosef | Adjustable button cinch anchor orthopedic fastener |
US5756483A (en) | 1993-03-26 | 1998-05-26 | Merkus; Franciscus W. H. M. | Pharmaceutical compositions for intranasal administration of apomorphine |
BE1006872A6 (nl) | 1993-03-26 | 1995-01-10 | Merkus Franciscus W H M | Nasale farmaceutische preparaten met dihydroergotamine (dhe). |
US5492688A (en) | 1993-04-28 | 1996-02-20 | The Center For Innovative Technology | Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent |
IL105658A (en) | 1993-05-11 | 1995-10-31 | Ultrasonic Dryer Ltd | Spray drying system |
TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
DE4322181A1 (de) | 1993-06-29 | 1995-01-12 | Hottinger Adolf Masch | Vorrichtung und Verfahren zum Greifen eines Gießereikerns, insbesondere eines Sohlenkerns |
GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
GB9313650D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
JP3750872B2 (ja) | 1993-07-14 | 2006-03-01 | 株式会社小松製作所 | 車両用エンジンの過給装置およびその制御方法 |
PL314294A1 (en) | 1993-11-08 | 1996-09-02 | Gillette Co | Method of producing particles using a hypercritical fluid, aerogel particles obtained thereby and antiperspirants containing such particles |
EP0655237A1 (de) | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medizinische Aerosolformulierung |
IT1265473B1 (it) | 1993-12-30 | 1996-11-22 | Otefal Srl | Procedimento per la produzione di polveri a granulometria controllata e prodotto in polvere cosi' ottenuto |
US5468768A (en) | 1994-01-06 | 1995-11-21 | Bristol-Myers Squibb Company | Antimigraine derivatives of indolylcycloalkanylamines |
US5595761A (en) | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
US5635210A (en) | 1994-02-03 | 1997-06-03 | The Board Of Regents Of The University Of Oklahoma | Method of making a rapidly dissolving tablet |
SI9400079B (sl) | 1994-02-15 | 2003-02-28 | Dr. Weidner Eckhard, Dipl. Ing. | Postopek in naprava za pridobivanje in frakcioniranje majhnih delcev iz raztopin nasičenih s plinom |
EP1462096B1 (en) | 1994-03-07 | 2008-12-10 | Nektar Therapeutics | Methods and compositions for pulmonary delivery of insulin |
GB9404945D0 (en) | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
US5508023A (en) | 1994-04-11 | 1996-04-16 | The Center For Innovative Technology | Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant |
KR100384353B1 (ko) | 1994-05-18 | 2003-10-04 | 네크타르 테라퓨틱스 | 인터페론의건조분말제형을제조하기위한방법및조성물 |
JPH0817132A (ja) | 1994-06-30 | 1996-01-19 | Rohm Co Ltd | 円盤状情報記録担体の再生装置 |
GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US5560543A (en) | 1994-09-19 | 1996-10-01 | Board Of Regents, The University Of Texas System | Heat-resistant broad-bandwidth liquid droplet generators |
GB9419536D0 (en) | 1994-09-28 | 1994-11-16 | Glaxo Inc | Medicaments |
US6117455A (en) | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
DE4438978A1 (de) | 1994-10-31 | 1996-05-02 | Helmut Wurzer | Elektrochirurgiegerät und Verfahren zu dessen Betrieb |
EP0710983B1 (de) | 1994-11-07 | 2001-02-28 | eupec Europäische Gesellschaft für Leistungshalbleiter mbH & Co. KG | Brücken-Modul |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
GB9425160D0 (en) | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
MX9504934A (es) | 1994-12-12 | 1997-01-31 | Morton Int Inc | Revestimientos en polvo de pelicula delgada lisa. |
GB9426252D0 (en) | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
US6013245A (en) | 1995-01-26 | 2000-01-11 | Glaxo Group Limited | Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant |
US5639475A (en) | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
ATE258813T1 (de) | 1995-04-14 | 2004-02-15 | Smithkline Beecham Corp | Vorrichtung zur dosierten inhalierung von beclomethason-diproprionat |
CN1113675C (zh) | 1995-04-14 | 2003-07-09 | 葛兰素惠尔康公司 | 丙酸福地卡松的计定剂量吸入器 |
CN1217654C (zh) | 1995-04-14 | 2005-09-07 | 史密丝克莱恩比彻姆公司 | 舒喘宁的计定剂量吸入器 |
ATE297773T1 (de) | 1995-04-14 | 2005-07-15 | Smithkline Beecham Corp | Dosierinhalator für salmeterol |
US5607697A (en) | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
US6576264B1 (en) | 1995-10-17 | 2003-06-10 | Skyepharma Canada Inc. | Insoluble drug delivery |
US5807578A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
GB9526392D0 (en) | 1995-12-22 | 1996-02-21 | Glaxo Group Ltd | Medicaments |
EP0885038B1 (en) | 1996-03-01 | 2011-06-15 | The University Of Kansas | Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents |
US5874029A (en) | 1996-10-09 | 1999-02-23 | The University Of Kansas | Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent |
GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US5776573A (en) | 1996-04-16 | 1998-07-07 | Cd Magic, Inc. | Compact disc revitalizer formulations and revitalizer |
US5648004A (en) | 1996-04-19 | 1997-07-15 | Simpson; Claudie | Kit and method to retrofit heating elements for curling iron holder |
DE19617487A1 (de) | 1996-05-02 | 1997-11-06 | Merck Patent Gmbh | Geschmacksverbesserung von Arzneimittelwirkstoffen |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6054488A (en) | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
US6284267B1 (en) | 1996-08-14 | 2001-09-04 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
EP0925061B1 (en) | 1996-08-22 | 2005-12-28 | Jagotec Ag | Compositions comprising microparticles of water-insoluble substances and method for preparing same |
US6068832A (en) | 1996-08-29 | 2000-05-30 | Schering Corporation | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
FR2753639B1 (fr) | 1996-09-25 | 1998-12-11 | Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede | |
CA2266629C (en) | 1996-10-01 | 2002-04-16 | Cima Labs Inc. | Taste-masked microcapsule compositions and methods of manufacture |
US5891885A (en) | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
US5813597A (en) | 1996-10-15 | 1998-09-29 | Ethicon Endo-Surgery, Inc. | Dual orientation dispenser carton |
GB9622173D0 (en) | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
US6077539A (en) | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
GB9702799D0 (en) | 1997-02-12 | 1997-04-02 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms |
IT1291779B1 (it) | 1997-02-17 | 1999-01-21 | Magnetek Spa | Procedimento per la realizzazione di circuiti stampati e circuiti stampati cosi'ottenuti |
GB9703673D0 (en) | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
US6236747B1 (en) | 1997-02-26 | 2001-05-22 | Acuity Imaging, Llc | System and method for image subtraction for ball and bumped grid array inspection |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
US6129905A (en) | 1997-04-21 | 2000-10-10 | Aeropharm Technology, Inc. | Aerosol formulations containing a sugar as a dispersant |
US5916125A (en) | 1997-05-16 | 1999-06-29 | Allison Engine Company, Inc. | Forced purge wave rotor |
US6120752A (en) | 1997-05-21 | 2000-09-19 | 3M Innovative Properties Company | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
SE9701956D0 (sv) | 1997-05-23 | 1997-05-23 | Astra Ab | New composition of matter |
US6315122B1 (en) | 1997-05-29 | 2001-11-13 | Mitsubishi Polyester Film, Llc | Palletless packaging system |
US6236647B1 (en) | 1998-02-24 | 2001-05-22 | Tantivy Communications, Inc. | Dynamic frame size adjustment and selective reject on a multi-link channel to improve effective throughput and bit error rate |
US6200293B1 (en) | 1997-08-27 | 2001-03-13 | Science Incorporated | Fluid delivery device with temperature controlled energy source |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US6153220A (en) | 1997-10-03 | 2000-11-28 | Elan Corporation, Plc | Taste-masked formulations |
NZ504021A (en) | 1997-10-17 | 2003-04-29 | Systemic Pulmonary Delivery Lt | Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication |
US6089911A (en) | 1997-12-05 | 2000-07-18 | The Whitaker Corporation | Apparatus and method for mounting a plurality of surface mount contacts |
GB9804379D0 (en) | 1998-03-02 | 1998-04-22 | Bradford Particle Design Ltd | Method of particle formation |
US6120613A (en) | 1998-04-30 | 2000-09-19 | Micell Technologies, Inc. | Carbon dioxide cleaning and separation systems |
SE9801287D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Incorporation of active substances in carrier matrixes |
SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
GB9808802D0 (en) | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
GB9810126D0 (ja) | 1998-05-13 | 1998-07-08 | Glaxo Group Ltd | |
GB9810559D0 (en) | 1998-05-15 | 1998-07-15 | Bradford Particle Design Ltd | Method and apparatus for particle formation |
SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
SE513162C2 (sv) | 1998-07-24 | 2000-07-17 | Allgon Ab | Antennanordning |
DE59911149D1 (de) | 1998-07-24 | 2004-12-30 | Jago Res Ag Muttenz | Medizinische aerosolformulierungen |
US6387410B1 (en) | 1998-09-10 | 2002-05-14 | Norton Healthcare Ltd | Anti-inflammatory pharmaceutical formulations |
US6190029B1 (en) | 1998-09-25 | 2001-02-20 | Stanley Electric Co., Ltd. | Headlamp with beam distribution switch mechanism |
US5992306A (en) | 1998-10-15 | 1999-11-30 | Century Machinery Corp. | Structure of a hand holding net basket for frying |
SE9804001D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New process |
SE9804003D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | A method of producing drug particles |
JP2002530322A (ja) | 1998-11-25 | 2002-09-17 | シーマ・ラブス・インコーポレイテッド | 味隠蔽迅速放出コーティング系 |
GB9825883D0 (en) | 1998-11-27 | 1999-01-20 | Aea Technology Plc | Formation of monodisperse particles |
US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
JP4020589B2 (ja) | 1999-01-14 | 2007-12-12 | 帝人株式会社 | 粉末体の定量供給装置 |
WO2000047236A1 (en) | 1999-02-12 | 2000-08-17 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
GEP20053473B (en) | 1999-03-26 | 2005-03-25 | Pozen Inc | High Potency Dihydroergotamine Compositions |
SE9901667D0 (sv) | 1999-05-07 | 1999-05-07 | Astra Ab | Method and device for forming particles |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
GB9915975D0 (en) | 1999-07-07 | 1999-09-08 | Bradford Particle Design Ltd | Method for the formation of particles |
US20020081266A1 (en) | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
GB9920558D0 (en) | 1999-08-31 | 1999-11-03 | Bradford Particle Design Ltd | Methods for particle formation and their products |
MXPA02002714A (es) | 1999-09-13 | 2003-10-14 | Sheffield Pharmaceuticals Inc | Sistema y metodo de control de flujo de aire en aerosol. |
US6346323B1 (en) | 1999-10-07 | 2002-02-12 | Sig Pack Systems Ag | Multi-layer synthetic film |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US6367471B1 (en) | 1999-11-01 | 2002-04-09 | Sheffield Pharmaceuticals, Inc. | Internal vortex mechanism for inhaler device |
AU4305101A (en) * | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
KR100311975B1 (ko) * | 1999-12-16 | 2001-10-17 | 윤종용 | 반도체소자 및 그 제조방법 |
KR20010088139A (ko) | 2000-03-10 | 2001-09-26 | 백승헌 | 텍스트 데이터 입력에 대응한 입모양 출력장치 및 그 방법 |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0011807D0 (en) | 2000-05-16 | 2000-07-05 | Quadrant Holdings Cambridge | Formulation for inhalation |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
US6620351B2 (en) | 2000-05-24 | 2003-09-16 | Auburn University | Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer |
US6451287B1 (en) | 2000-05-26 | 2002-09-17 | Smithkline Beecham Corporation | Fluorinated copolymer surfactants and use thereof in aerosol compositions |
US6656492B2 (en) | 2000-06-30 | 2003-12-02 | Yamanouchi Pharmaceutical Co., Ltd. | Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
FR2812040B1 (fr) | 2000-07-18 | 2003-02-07 | Cit Alcatel | Carter monobloc pour pompe a vide |
EP1373576A4 (en) | 2000-07-24 | 2005-06-15 | Inst Of Molecul & Cell Biology | NUCLEIC ACIDS AND METHODS FOR DETECTING VIRAL INFECTION, DISCOVERING CANDIDATE ANTI-VIRAL DRUGS AND DETERMINING DRUG RESISTANCE OF VIRAL ISOLATES |
US6941569B2 (en) | 2000-08-18 | 2005-09-06 | Hewlett-Packard Development Company, L.P. | System and method utilizing a conductive brush for providing power signals to a cartridge access device |
US6406681B1 (en) | 2000-08-21 | 2002-06-18 | Aeropharm Technology, Inc. | Method of treating a systemic disease |
AU2001286832A1 (en) | 2000-08-30 | 2002-03-13 | Lilly Icos Llc | Method for treatment of migraine using PDE5 inhibitors |
US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
FR2815540B1 (fr) | 2000-10-19 | 2005-06-10 | Separex Sa | Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote |
GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
US6932861B2 (en) | 2000-11-28 | 2005-08-23 | Fmc Corporation | Edible PGA coating composition |
GB0102075D0 (en) | 2001-01-26 | 2001-03-14 | Astrazeneca Ab | Process |
US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US20030198669A1 (en) * | 2001-07-05 | 2003-10-23 | R.T. Alamo Ventures I, Llc | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine |
US20030008005A1 (en) * | 2001-07-05 | 2003-01-09 | R.T. Alamo Ventures, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
US20030017175A1 (en) * | 2001-07-05 | 2003-01-23 | R.T. Alamo Ventures I, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
US20030022910A1 (en) | 2001-07-05 | 2003-01-30 | R.T. Alamo Ventures I, Inc. | Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine |
US6685951B2 (en) | 2001-07-05 | 2004-02-03 | R. T. Alamo Ventures I, Inc. | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine |
TW586963B (en) | 2001-07-20 | 2004-05-11 | Nektar Therapeutics Uk Ltd | Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
GB0117696D0 (en) | 2001-07-20 | 2001-09-12 | Bradford Particle Design Plc | Particle information |
US20030181462A1 (en) | 2001-08-17 | 2003-09-25 | Boehringer Ingelheim Pharma Kg | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine |
US20030091513A1 (en) * | 2001-10-03 | 2003-05-15 | Mohsen Nahed M. | Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media |
AU2003208761A1 (en) | 2002-02-21 | 2003-09-09 | Amarin Development Ab | A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use |
EP1490031A1 (en) | 2002-03-07 | 2004-12-29 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
BRPI0308445A2 (pt) | 2002-03-08 | 2016-08-02 | M S Ind Swift Ltd | complexos de rápida dissolução, diretamente compressíveis, sem sabor e formulações farmacêuticas dos mesmos |
DE10212564B4 (de) * | 2002-03-12 | 2007-04-19 | Neurobiotec Gmbh | 1-Allyl-ergotalkaloid-Derivate und ihre Verwendung zur Prophylaxe und Therapie von Migräne |
US7582284B2 (en) | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
JP2004184809A (ja) | 2002-12-05 | 2004-07-02 | Nitto Denko Corp | 偏光板の製造方法、偏光板およびそれを用いた画像表示装置 |
GB0300338D0 (en) | 2003-01-08 | 2003-02-05 | Bradford Particle Design Ltd | Particle formation |
AU2003900081A0 (en) | 2003-01-08 | 2003-01-23 | George Moore | Drilling jig |
GB0300339D0 (en) | 2003-01-08 | 2003-02-05 | Bradford Particle Design Ltd | Particle formation |
GB0304636D0 (en) | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
MXPA05011343A (es) | 2003-05-08 | 2005-12-12 | Nektar Therapeutics Uk Ltd | Materiales particulados. |
JP2007516259A (ja) | 2003-12-09 | 2007-06-21 | メッドクリスタルフォームズ、エルエルシー | 活性剤との混合相共結晶の調製方法 |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20060246070A1 (en) | 2004-09-30 | 2006-11-02 | Heavner George A | Methods and compositions for treating renal cell carcinoma related pathologies |
US20060240043A1 (en) | 2004-10-08 | 2006-10-26 | Meyerson Laurence R | Methods and compositions for treating migraine pain |
US20090232898A1 (en) | 2005-03-28 | 2009-09-17 | Anders Pettersson | Pharmaceutical Compositions Useful in the Treatment of Migraine |
US7219664B2 (en) * | 2005-04-28 | 2007-05-22 | Kos Life Sciences, Inc. | Breath actuated inhaler |
CA2615378C (en) | 2005-07-15 | 2015-02-17 | Map Pharmaceuticals, Inc. | Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof |
SE530445C2 (sv) | 2006-10-23 | 2008-06-10 | Volvo Lastvagnar Ab | Hyttupphängningssystem |
EP2117506A2 (en) | 2006-12-13 | 2009-11-18 | Stephen M. Tuel | Methods of making pharmaceutical components for customized drug products |
AU2008214205B2 (en) | 2007-02-11 | 2014-04-24 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile |
GB2448183A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
WO2009071329A1 (en) | 2007-12-07 | 2009-06-11 | Pact Xpp Technologies Ag | Using function calls as compiler directives |
TW200938236A (en) | 2008-03-13 | 2009-09-16 | Fei-Peng Lin | Deodorization material composition, manufacturing method thereof, and deodorization method |
EP2105189A1 (de) | 2008-03-27 | 2009-09-30 | Siemens Aktiengesellschaft | Verfahren und Vorrichtung zum Abtrennen von Kohlendioxid aus Rauchgas einer fossilbefeuerten Kraftwerksanlage |
EP2756756B1 (en) | 2008-04-28 | 2016-01-06 | Zogenix, Inc. | Novel formulations for treatment of migraine |
CA2730419A1 (en) * | 2008-07-11 | 2010-01-14 | Map Pharmaceuticals, Inc. | Containers for aerosol drug delivery |
WO2010148519A1 (en) * | 2009-06-25 | 2010-12-29 | Queen's University At Kingston | Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist |
EP2322326A1 (en) | 2009-11-13 | 2011-05-18 | Frederik Daniël Nossbaum | Multifunctional tool |
-
2008
- 2008-02-11 AU AU2008214205A patent/AU2008214205B2/en active Active
- 2008-02-11 CN CN201410379903.5A patent/CN104188907A/zh active Pending
- 2008-02-11 KR KR1020167023885A patent/KR20160106200A/ko not_active Application Discontinuation
- 2008-02-11 CA CA2677838A patent/CA2677838C/en active Active
- 2008-02-11 ES ES08725456.1T patent/ES2691033T3/es active Active
- 2008-02-11 MX MX2009008582A patent/MX2009008582A/es active IP Right Grant
- 2008-02-11 WO PCT/US2008/001829 patent/WO2008097664A1/en active Application Filing
- 2008-02-11 EP EP20110191793 patent/EP2425819A1/en not_active Withdrawn
- 2008-02-11 JP JP2009549138A patent/JP5825757B2/ja active Active
- 2008-02-11 CN CN200880011629A patent/CN101677954A/zh active Pending
- 2008-02-11 HU HUE11191794A patent/HUE026884T2/en unknown
- 2008-02-11 PL PL11191794T patent/PL2425820T3/pl unknown
- 2008-02-11 SI SI200831425T patent/SI2425820T1/sl unknown
- 2008-02-11 US US12/069,667 patent/US8148377B2/en active Active
- 2008-02-11 DK DK11191794.4T patent/DK2425820T3/en active
- 2008-02-11 KR KR1020097019032A patent/KR20090129998A/ko not_active Application Discontinuation
- 2008-02-11 KR KR1020157007681A patent/KR20150041804A/ko not_active Application Discontinuation
- 2008-02-11 EP EP08725456.1A patent/EP2120875B1/en active Active
- 2008-02-11 DK DK08725456.1T patent/DK2120875T3/en active
- 2008-02-11 PT PT111917944T patent/PT2425820E/pt unknown
- 2008-02-11 EP EP11191794.4A patent/EP2425820B1/en active Active
- 2008-02-11 ES ES11191794.4T patent/ES2538082T3/es active Active
-
2009
- 2009-08-11 IL IL200333A patent/IL200333A/en active IP Right Grant
- 2009-08-13 ZA ZA2009/05628A patent/ZA200905628B/en unknown
- 2009-08-26 US US12/548,292 patent/US7994197B2/en active Active
- 2009-08-26 US US12/548,304 patent/US20100081664A1/en not_active Abandoned
-
2010
- 2010-07-19 US US12/839,190 patent/US8119639B2/en active Active
-
2012
- 2012-02-27 US US13/406,391 patent/US20120245179A1/en not_active Abandoned
-
2013
- 2013-08-05 JP JP2013162032A patent/JP5908439B2/ja active Active
-
2014
- 2014-06-23 AU AU2014203389A patent/AU2014203389B2/en active Active
- 2014-10-14 US US14/514,322 patent/US20150057287A1/en not_active Abandoned
-
2015
- 2015-06-08 HK HK15105429.3A patent/HK1204918A1/xx unknown
- 2015-06-26 CY CY20151100551T patent/CY1116546T1/el unknown
- 2015-10-23 US US14/921,860 patent/US9833451B2/en active Active
- 2015-12-03 JP JP2015236885A patent/JP6209198B2/ja active Active
- 2015-12-03 JP JP2015236886A patent/JP2016040317A/ja active Pending
-
2016
- 2016-11-04 AU AU2016253689A patent/AU2016253689B2/en active Active
-
2017
- 2017-03-28 US US15/471,334 patent/US10172853B2/en active Active
-
2018
- 2018-09-11 US US16/127,734 patent/US20190247393A1/en not_active Abandoned
-
2019
- 2019-12-05 US US16/704,867 patent/US20200352939A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005025506A2 (en) * | 2003-09-10 | 2005-03-24 | Map Pharmaceuticals, Inc. | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
Non-Patent Citations (2)
Title |
---|
JPN6013015076; SILBERSTEIN,S.D. et al: Headache Vol.43, No.2, 2003, p.144-66 * |
JPN6013015078; WEITZEL,K.W. et al: Pharmacotherapy Vol.19, No.8, 1999, p.957-73 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013224331A (ja) * | 2007-02-11 | 2013-10-31 | Map Pharmaceuticals Inc | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 |
JP2021510155A (ja) * | 2018-01-05 | 2021-04-15 | インペル ニューロファーマ インコーポレイテッド | 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達 |
JP7317020B2 (ja) | 2018-01-05 | 2023-07-28 | インペル ファーマシューティカルズ インコーポレイテッド | 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6209198B2 (ja) | 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法 | |
DK2522365T3 (en) | Compositions comprising azelastine and methods for its use | |
JP2009529539A (ja) | 呼吸器障害を治療するための方法および組成物 | |
US20040142944A1 (en) | Compositions for nasal application | |
CN116033893A (zh) | 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110118 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130329 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130624 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130701 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130726 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130805 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20140124 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140131 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140325 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140724 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140908 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140926 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151013 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5825757 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |